Based on the Can Fite Biopharma Ltd ADR stock forecast from 1 analysts, the average analyst target price for Can Fite Biopharma Ltd ADR is USD 10.00 over the next 12 months. Can Fite Biopharma Ltd ADR’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Can Fite Biopharma Ltd ADR is Bearish, which is based on 2 positive signals and 8 negative signals. At the last closing, Can Fite Biopharma Ltd ADR’s stock price was USD 2.65. Can Fite Biopharma Ltd ADR’s stock price has changed by -1.85% over the past week, +29.90% over the past month and +1,280.21% over the last year.
No recent analyst target price found for Can Fite Biopharma Ltd ADR
No recent average analyst rating found for Can Fite Biopharma Ltd ADR
Company Overview Can Fite Biopharma Ltd ADR
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel. Read Less
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, whic...Read More
Frequently Asked Questions About Can Fite Biopharma Ltd ADR (CANF) Stock
Based on ratings from 1 analysts Can Fite Biopharma Ltd ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on CANF's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for CANF is USD 10.00 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 10.
Unfortunately we do not have enough data on CANF's stock to indicate if its overvalued.
The last closing price of CANF's stock was USD 2.65.
The most recent market capitalization for CANF is USD 0.02B.
Based on targets from 1 analysts, the average taret price for CANF is projected at USD 10.00 over the next 12 months.
This means that CANF's stock price may go up by +277.36% over the next 12 months.
We can't find any ETFs which contains Can Fite Biopharma Ltd ADR's stock.
As per our most recent records Can Fite Biopharma Ltd ADR has 8 Employees.
Can Fite Biopharma Ltd ADR's registered address is 26 Ben Gurion Street, Ramat Gan, Israel, 5257346.
You can get more information about it from Can Fite Biopharma Ltd ADR's website at https://www.canfite.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Can Fite Biopharma Ltd ADR (CANF) Stock
Based on ratings from 1 analysts Can Fite Biopharma Ltd ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on CANF's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for CANF is USD 10.00 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 10.
Unfortunately we do not have enough data on CANF's stock to indicate if its overvalued.
The last closing price of CANF's stock was USD 2.65.
The most recent market capitalization for CANF is USD 0.02B.
Based on targets from 1 analysts, the average taret price for CANF is projected at USD 10.00 over the next 12 months.
This means that CANF's stock price may go up by +277.36% over the next 12 months.
We can't find any ETFs which contains Can Fite Biopharma Ltd ADR's stock.
As per our most recent records Can Fite Biopharma Ltd ADR has 8 Employees.
Can Fite Biopharma Ltd ADR's registered address is 26 Ben Gurion Street, Ramat Gan, Israel, 5257346.
You can get more information about it from Can Fite Biopharma Ltd ADR's website at https://www.canfite.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CANF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
